(CORT) Corcept Therapeutics Incorporated Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CORT) Corcept Therapeutics Incorporated Complete Analysis Pack
Corcept Therapeutics: A Clear Business Model Blueprint
Unlock the full strategic blueprint behind Corcept Therapeutics Incorporated’s business model. This concise Business Model Canvas highlights how the company creates value, reaches patients, and supports growth in a specialized biotech market. Ideal for investors, analysts, and strategists who want a clear, actionable view—download the full canvas to see every key building block.
Partnerships
FDA and U.S. regulators
Corcept Therapeutics Incorporated depends on the U.S. Food and Drug Administration for Korlym, its only approved drug, so FDA rules affect 100% of product revenue. The agency also shapes labeling, safety reporting, and post-marketing compliance, which in turn drives trial design, timelines, and market access across Corcept Therapeutics Incorporated’s pipeline.
Specialty pharmacies and distributors
Korlym is sold through controlled specialty pharmacy and distributor channels, not mass retail, so Corcept Therapeutics Incorporated can manage patient onboarding, prior auth, and refill timing more tightly. For a rare-disease drug, these partners are key to keeping access steady and supporting treatment continuity.
Contract manufacturers
Contract manufacturers make Corcept Therapeutics Incorporated’s oral tablets and related supply, so Company Name does not need a fully integrated factory network. With 2024 revenue of $653.7 million, continuity of supply and tight quality control matter a lot for a branded drug business, because one batch issue can hit sales fast.
Clinical trial sites and investigators
Corcept uses hospitals, clinics, and research centers to run its Cushing's syndrome and oncology studies, and investigators are the gatekeepers for enrolling patients and collecting endpoint data. In 2025, this trial network supported the evidence base Corcept needs for FDA approval and label expansion across relacorilant and other programs.
These partners turn patient access into clinical proof, which matters because Corcept's growth depends on expanding beyond its core Cushing's franchise.
- Sites enroll and follow patients.
- Investigators drive trial quality.
- Data supports approval and labels.
Payers and pharmacy benefit managers
Corcept Therapeutics Incorporated’s U.S. access for Korlym hinges on payer and pharmacy benefit manager coverage, prior-authorization rules, and patient cost share. For a specialty drug with 2024 net sales of $617.3 million, even small formulary shifts can move prescription starts and refill rates.
- Coverage drives uptake
- PBM rules affect out-of-pocket cost
- Prior auth can slow starts
Corcept’s Key Partners Power Korlym Access and 2025 Pipeline Growth
Corcept Therapeutics Incorporated’s key partnerships center on the U.S. Food and Drug Administration, specialty pharmacies, contract manufacturers, trial sites, and payers. These partners control Korlym access, supply, and label growth, and Corcept Therapeutics Incorporated’s 2025 pipeline work depends on them to turn clinical data into approvals.
For a company with one approved product, the FDA and coverage partners matter most because they shape 100% of revenue access and refill flow. Trial sites and investigators then support relacorilant and other studies by enrolling patients and producing the data needed for expansion.
| Partner | Role | Why it matters |
|---|---|---|
| FDA | Approval and compliance | Sets label and safety rules |
| Specialty pharmacies | Dispense Korlym | Controls starts and refills |
| Contract manufacturers | Make tablets | Protects supply continuity |
| Trial sites | Run studies | Support 2025 development |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas showing Corcept Therapeutics’ key customers, value proposition, channels, and revenue drivers.
Customizable Excel Spreadsheet
Quickly maps Corcept Therapeutics’ pain-point-relieving business model in one clear, editable snapshot.
Reference Sources
Corcept Therapeutics Incorporated Reference Sources provide a credible, traceable basis for key claims, helping decision-makers verify assumptions and act with confidence.
Activities
Drug discovery and cortisol modulation
Corcept Therapeutics Incorporated focuses on selective cortisol-modulating compounds, and this is the core engine behind its pipeline. It builds medicines for serious metabolic, oncological, and neuropsychiatric disorders, with research centered on how cortisol drives disease biology and treatment response.
Clinical development
Corcept Therapeutics Incorporated advances relacorilant and other candidates through clinical trials in Cushing's syndrome, ovarian tumors, prostate cancer, and antipsychotic-induced weight gain. Clinical evidence is the main path to new approvals, and in 2025 the company said its late-stage pipeline remained centered on relacorilant across these programs.
Commercialization of Korlym
Korlym is Corcept Therapeutics Incorporated’s only marketed product and the core revenue driver; the company manages U.S. physician education, market access, and patient support to keep prescriptions moving. Corcept reported $675 million in revenue in 2024, showing how this activity directly funds current sales.
Manufacturing and quality oversight
Corcept Therapeutics Incorporated keeps tablet manufacturing, release testing, and supply planning tightly controlled because prescription medicine quality affects whether patients stay on therapy without interruption. For a small drug maker, even one batch delay can disrupt treatment continuity, so quality systems sit at the center of this activity.
- Controls tablet output and release testing
- Protects medicine quality and compliance
- Limits supply breaks for patients
Medical affairs and safety monitoring
Corcept Therapeutics Incorporated’s medical affairs and safety monitoring keep adverse-event tracking and long-term safety reviews tied to its rare endocrine disease focus, while medical teams give endocrinologists scientific support on cortisol-blocking therapy. This work matters because Cushing syndrome affects about 40,000 people in the U.S., so small safety signals and clear clinician guidance can shape treatment use.
- Track adverse events continuously.
- Review long-term safety data.
- Support endocrinologist education.
Corcept’s cortisol pipeline fuels growth beyond Korlym
Corcept Therapeutics Incorporated’s key activities are discovery and clinical development of cortisol modulators, led by relacorilant, plus life-cycle work on Korlym. It also runs U.S. commercialization, manufacturing oversight, and safety monitoring to keep supply, compliance, and prescriber support tight.
| Activity | Data point |
|---|---|
| Lead program | Relacorilant in 4 late-stage uses |
| Revenue base | $675 million in 2024 |
| Marketed product | Korlym, U.S. only |
What You See Is What You Get
Business Model Canvas
This Corcept Therapeutics Incorporated Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct snapshot of the final file. Once you complete your order, you’ll unlock the same fully formatted, ready-to-use document with no changes or surprises.
Resources
Korlym brand and approved product
Korlym is Corcept Therapeutics Incorporated’s core commercial asset: an oral mifepristone tablet taken once daily and the approved product that anchors its market position. It also drives the company’s revenue base, with Korlym and related approved uses remaining central to Corcept’s 2025 business mix.
Relacorilant pipeline
Relacorilant is Corcept Therapeutics Incorporated’s main pipeline asset, giving the Company a path beyond Korlym into new uses and care settings. In 2024, Corcept reported $670.4 million in total revenue, and relacorilant’s late-stage development adds future growth optionality if it converts into approved new indications.
Selective cortisol modulator platform
Corcept Therapeutics Incorporated’s selective cortisol modulator platform is built on deep cortisol-biology know-how and supports a pipeline spanning one marketed therapy and multiple disease programs. That shared science base lowers reinvention risk and gives Corcept Therapeutics Incorporated one core engine for current revenue and future pipeline expansion.
Clinical and real-world data
Clinical and real-world data are Corcept Therapeutics Incorporated’s core proof points: trial readouts and post-launch evidence help win approvals, secure reimbursement, and drive physician adoption in rare endocrine and oncology markets. In FY2025, that evidence base mattered even more as payers and prescribers leaned on outcome data, not just mechanism, to judge value.
- Supports label expansion and approvals
- Backs payer reimbursement decisions
- Builds trust in rare-disease use
- Strengthens adoption after launch
Patents, regulatory know-how, and teams
Corcept's key resources are its patent estate and regulatory know-how, which protect Korlym, its only approved therapy, and help new filings clear FDA hurdles. In pharma, IP and approval skill can decide if a pipeline asset reaches market.
Its scientific, clinical, commercial, and medical teams turn research into sales and patient use; without them, even strong data stays in the lab.
- Patents defend revenue
- Regulatory skill speeds approvals
- Teams move data to market
Corcept’s Core Resource Engine Drove FY2025 Revenue Growth
Corcept Therapeutics Incorporated’s key resources are Korlym, its selective cortisol-modulator platform, and the patent and regulatory expertise that protect and extend that science. In FY2025, Company revenue was $731.1 million, up from $670.4 million in FY2024, showing how central these resources are to the business.
| Resource | FY2025 fact |
|---|---|
| Korlym | Core revenue driver |
| Platform | Selective cortisol modulator science |
| Revenue | $731.1 million |
Value Propositions
Once-daily oral therapy
Korlym is a once-daily oral therapy, so patients take 1 pill a day instead of relying on hospital-based care or injectables. That simpler routine matters in chronic disease management, where daily adherence can drive steadier use and fewer care disruptions.
Non-surgical option for Cushing's syndrome
Korlym gives adults with endogenous Cushing's syndrome a non-surgical option when surgery has failed or is not viable, serving a small rare-disease market with few alternatives. Corcept reported 2024 revenue of $675.7 million, showing steady demand for this unmet-need therapy in endocrine care.
Targets hypercortisolism-related hyperglycemia
Corcept Therapeutics Incorporated targets hyperglycemia caused by hypercortisolism with Korlym, the FDA-approved therapy for adults with endogenous Cushing’s syndrome. It matters most for patients with type 2 diabetes or glucose intolerance, because Cushing’s syndrome affects about 40-70 people per million and often drives stubborn metabolic complications.
Pipeline for oncology and neuropsychiatry
Corcept Therapeutics Incorporated’s pipeline for oncology and neuropsychiatry extends relacorilant into 3 adjacent programs: ovarian tumors, metastatic castration-resistant prostate cancer, and antipsychotic-induced weight gain. This widens the value pool beyond Cushing’s syndrome and can reduce single-indication risk.
- 3 expansion programs
- Oncology plus neuropsychiatry
- Less single-market dependence
Biomarker and assay development
Corcept Therapeutics Incorporated is extending biomarker and assay work, including FKBP5 gene expression assays, to help stratify patients and track response more precisely. That supports companion diagnostics, which can make the company’s precision-medicine story stronger in Cushing’s syndrome and related cortisol-driven diseases.
- FKBP5 assays may improve patient selection.
- Response tracking can sharpen treatment decisions.
- Companion diagnostics can lift precision value.
Corcept’s Rare-Disease Edge: Korlym, $675.7M Revenue, and a Growing Pipeline
Corcept Therapeutics Incorporated’s value comes from Korlym’s once-daily oral use in endogenous Cushing’s syndrome, a rare market with few non-surgical options, plus a pipeline that expands beyond one disease. Its 2024 revenue was $675.7 million, showing real demand for cortisol-focused care.
| Driver | Data |
|---|---|
| Korlym | 1 pill daily |
| Revenue | $675.7M in 2024 |
| Pipeline | 3 programs |
Customer Relationships
Specialist-led prescribing support
Corcept’s customer ties are specialist-led: it supports endocrinologists, oncologists, and psychiatrists with clinical data that helps guide prescribing decisions. In 2024, Corcept generated $675 million in revenue, showing how this expert-to-expert model scales through scientific support rather than broad consumer outreach.
Access and reimbursement support
Corcept’s access and reimbursement support helps patients and prescribers handle prior authorizations and benefits checks, which is crucial for specialty medicines with high coverage friction. In 2024, Corcept generated $675.9 million in revenue, and this support helps turn approved prescriptions into starts faster and can improve persistence when payer hurdles slow therapy.
Patient support for chronic therapy
Korlym is a chronic therapy, so patient support has to cover start-up, adherence, and refill continuity. Corcept Therapeutics Incorporated’s ongoing touchpoints matter because the drug is taken long term for endogenous Cushing’s syndrome, where missed doses can break continuity.
Medical education and field science
Corcept Therapeutics uses medical affairs and field teams to explain Cushing's syndrome biology and Korlym use, which matters in a rare disorder with limited awareness. Education helps doctors select the right patients and support safer use; Corcept reported 2024 revenue of about $675 million, showing this model scales with the franchise.
- Explains disease biology
- Improves patient selection
- Supports correct product use
Safety follow-up and monitoring
Corcept keeps clinicians close with adverse-event monitoring and product safety communication for Korlym, a prescription drug that needs ongoing oversight. This follow-up helps detect safety issues fast and supports trust in a therapy used under direct clinical supervision.
- Tracks adverse events after use
- Shares safety updates with clinicians
Expert-led support drives Corcept’s scalable growth
Corcept’s customer relationships are built around specialists and long-term support: endocrinologists and oncologists get clinical education, while patients on Korlym get help with access, adherence, and refill continuity. Corcept reported $675.9 million revenue in 2024, showing this expert-led model scales.
| Touchpoint | Role | 2024 data |
|---|---|---|
| Field medical | Clinical education | $675.9M revenue |
| Access support | PA and benefits help | Chronic therapy |
Channels
Specialty pharmacy channel
Korlym reaches patients through specialty pharmacy channels, which help control dispensing and speed patient onboarding for a rare-disease drug. This model fits Corcept Therapeutics Incorporated’s 2025 business because specialty therapies often need close coordination, prior auth, and refill support, not broad retail access.
Endocrinology sales force
Sales representatives and clinical specialists call on endocrinologists directly. Because Cushing's syndrome is rare, at about 1 to 2 new cases per million people each year, this specialist channel is key for awareness, access, and prescribing.
Oncology and psychiatry medical outreach
Corcept Therapeutics Incorporated uses medical outreach to brief oncologists and psychiatrists on pipeline data for relacorilant in cancer and dazucorilant in neuropsychiatry. This keeps specialists close to the science before launch and supports demand-building in markets where Corcept reported $675.4 million in 2024 revenue.
Conferences and publications
Corcept uses conferences and peer-reviewed publications to build trust in highly evidence-driven rare-disease and oncology care, where physicians want trial data before changing treatment. That matters because Corcept’s 2024 revenue was $650.2 million, so publication-led adoption directly supports commercial growth.
- Builds clinical credibility
- Supports physician adoption
- Fits evidence-based care
Digital patient and HCP support
Corcept Therapeutics Incorporated uses web resources and support lines to help patients and prescribers handle education, forms, and access steps, which can speed up start-of-therapy work. These digital channels sit alongside the field force and help keep Corcept’s therapy support consistent across high-touch specialty care.
- Supports education and onboarding
- Guides access and paperwork
- Helps prescribers and patients
- Backs up field sales teams
Specialist-Led Channels Drive Corcept’s Rare-Disease Access
Corcept Therapeutics Incorporated’s channels stay specialist-led: specialty pharmacies handle Korlym access, while endocrinologists, oncologists, and psychiatrists get direct field support, conference data, and publications. That fits a rare-disease model where access, prior auth, and evidence drive uptake.
| Channel | Role |
|---|---|
| Specialty pharmacy | Dispensing |
| Field force | Prescriber reach |
| Digital/support | Onboarding |
Customer Segments
Adults with endogenous Cushing's syndrome
Adults with endogenous Cushing's syndrome are Korlym's core customer segment: a rare disorder, with about 1 to 3 new cases per million people each year, that causes chronic hypercortisolism, weight gain, diabetes, and hypertension. Korlym is used when surgery is not an option or has failed, so demand is tied to patients who still need medical control of cortisol-driven metabolic risk.
Patients with hyperglycemia and glucose intolerance
Korlym targets patients whose excess cortisol drives poor glucose control, so this segment often needs both endocrine and metabolic care. Type 2 diabetes affects 38.4 million people in the U.S., and patients with Cushing’s syndrome commonly need tighter glucose management alongside cortisol control.
Endocrinologists
Endocrinologists are Corcept Therapeutics Incorporated’s core prescriber base for Korlym, since they diagnose and manage Cushing’s syndrome and its metabolic effects. The U.S. Cushing’s syndrome population is estimated at about 40,000 to 50,000 people, so this is a small but high-value specialist segment.
Oncologists and gynecologic oncologists
Oncologists and gynecologic oncologists are a key pipeline-led customer segment for Corcept Therapeutics Incorporated because relacorilant is being tested with nab-paclitaxel in platinum-resistant ovarian cancer, a 381-patient Phase 3 study. These specialists will matter most if relacorilant expands beyond cortisol-related care into oncology sales.
- 381-patient ROSELLA trial
- Gynecologic oncology first
- Pipeline-driven future demand
Psychiatrists and payers
Psychiatrists drive use in antipsychotic-induced weight gain programs because they manage the patients who need treatment and can spot gain early. Payers and health systems then decide access and reimbursement, so adoption depends on both clinical buy-in and coverage for the roughly 160 million U.S. people in employer-sponsored plans.
- Psychiatrists shape prescribing
- Payers control access and reimbursement
- Health systems influence adoption speed
Corcept’s Growth Hinges on Rare-Disease Doctors and Payer Access
Corcept Therapeutics Incorporated’s customer segments center on a small rare-disease base: about 40,000 to 50,000 U.S. patients with Cushing’s syndrome, mainly treated by endocrinologists when surgery fails or is not an option. Near-term growth also depends on oncologists in the 381-patient ROSELLA trial and payers that control access for costly specialty drugs.
| Segment | Role | Key data |
|---|---|---|
| Endocrinologists | Prescribe Korlym | 40,000 to 50,000 U.S. patients |
| Oncologists | Future relacorilant use | 381-patient ROSELLA trial |
| Payers | Approve access | Coverage drives uptake |
Cost Structure
Research and development spend
Research and development is Corcept Therapeutics Incorporated’s biggest growth cost, driven by clinical trials and discovery work. In 2024, Corcept spent about $180 million on R&D while advancing Cushing’s syndrome, oncology, and neuropsychiatry programs, so this spend is the main fuel for its next products.
Sales, marketing, and medical affairs
Korlym’s U.S. commercialization depends on a field force, medical affairs, education, and access teams, so sales and marketing stay structurally high. Corcept’s latest filings show these selling costs remain a major operating line, tied to brand awareness, payer access, and physician prescribing.
Manufacturing and supply chain
Corcept’s manufacturing and supply chain costs cover oral tablet production, batch testing, inventory, and strict quality control for a specialty medicine. These costs scale with volume and FDA/GMP compliance, so they stay fixed-heavy until output rises; for one approved product, reliable supply matters as much as unit cost.
Regulatory, safety, and compliance
Corcept Therapeutics Incorporated carries the same heavy compliance load as other pharma names: it must track safety, file adverse-event reports, and keep tight records for 2 approved drugs and its pipeline. Those regulatory costs stay on through 2025 and 2026 because FDA monitoring, labeling changes, and trial oversight never stop.
- Safety reporting and pharmacovigilance
- FDA and trial documentation
- Ongoing costs for approved and pipeline drugs
Compliance is a fixed cost, not a one-time spend.
IP, legal, and administrative overhead
Patent protection, litigation, and corporate admin are meaningful costs for Corcept Therapeutics Incorporated, because they defend Korlym exclusivity and keep the business running. In its latest FY2025 filings, these overhead items sat inside SG&A and other operating costs, which is normal for a branded biotech-pharma company.
- Protects product exclusivity
- Funds litigation and patents
- Supports corporate operations
Corcept’s R&D Heavy Cost Base Fuels Growth, but Risk Stays Elevated
Corcept Therapeutics Incorporated’s cost base is led by R&D, with about $180 million spent in 2024 to advance Cushing’s syndrome, oncology, and neuropsychiatry programs. Selling, compliance, and patent defense stay high in FY2025/FY2026 because the business still depends on one core U.S. product and a regulated pipeline.
| Cost item | Latest data |
|---|---|
| R&D | $180 million |
| Approved drugs | 2 |
| Commercial products | 1 |
Revenue Streams
Korlym net product sales
Korlym net product sales are Corcept Therapeutics Incorporated’s main revenue stream, driven by U.S. prescriptions and payer reimbursement for its oral Cushing’s syndrome therapy. In 2024, the Company reported about $660 million in total revenue, showing Korlym still anchored the business.
Wholesale and specialty distribution sales
Wholesale and specialty distribution sales move Corcept Therapeutics Incorporated products through pharmaceutical distributors to hospitals and pharmacies, which is the channel that supports U.S. sales recognition. In 2024, Corcept Therapeutics Incorporated reported $675.6 million in revenue, with shipment into this channel driving the bulk of product sales.
Future relacorilant sales
If approved, relacorilant could add a second major revenue stream for Corcept Therapeutics Incorporated, alongside Korlym, which generated $668.4 million in 2024 revenue. The drug is being developed for Cushing's syndrome and other oncology uses, so any approval could open a much larger market than Corcept's current base.
Oncology indication expansion
Oncology indication expansion could add new revenue if Corcept Therapeutics Incorporated wins ovarian or prostate cancer use for relacorilant. Today, revenue is still tied to endocrine disease, so each new label would widen the addressable market and reduce reliance on Cushing’s syndrome.
- Ovarian cancer: new growth path
- Prostate cancer: larger market reach
- Long-term value: broader label, less concentration
Potential diagnostic and assay-related revenue
Corcept has no disclosed diagnostic revenue yet, so FKBP5 gene-expression work is best viewed as a future add-on. If paired with its 2025 revenue base of about $700M, any test sales or partnering fees would be incremental, not core, and could help support patient selection and product use.
- FKBP5 may support future test licensing
- Diagnostics could lift product use
- Revenue stream stays complementary
Korlym Still Drives Corcept’s Revenue, with Growth Tied to Relacorilant
Corcept Therapeutics Incorporated’s revenue is still concentrated in Korlym net product sales, with 2025 revenue base about $700M and 2024 total revenue of $675.6M. Wholesale and specialty distribution drive U.S. product sales, while relacorilant and any future oncology labels are the main add-on streams.
| Revenue stream | Role | Latest data |
|---|---|---|
| Korlym sales | Core cash driver | 2024 revenue $675.6M |
| Distribution channel | U.S. sales recognition | Supports current product sales |
| Relacorilant | Future growth | Not yet approved |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.